Drelich et al., 2024 - Google Patents

Characterization of unique pathological features of COVID-associated coagulopathy: studies with AC70 hACE2 transgenic mice highly permissive to SARS-CoV-2 …

Drelich et al., 2024

View HTML
Document ID
1735938244759878071
Author
Drelich A
Rayavara K
Hsu J
Saenkham-Huntsinger P
Judy B
Tat V
Ksiazek T
Peng B
Tseng C
Publication year
Publication venue
PLoS pathogens

External Links

Snippet

COVID-associated coagulopathy seemly plays a key role in post-acute sequelae of SARS- CoV-2 infection. However, the underlying pathophysiological mechanisms are poorly understood, largely due to the lack of suitable animal models that recapitulate key clinical …
Continue reading at journals.plos.org (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Similar Documents

Publication Publication Date Title
Legrand et al. Pathophysiology of COVID-19-associated acute kidney injury
Henry et al. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: a novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis
Bourgonje et al. Angiotensin‐converting enzyme 2 (ACE2), SARS‐CoV‐2 and the pathophysiology of coronavirus disease 2019 (COVID‐19)
Jin et al. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches
Perico et al. SARS-CoV-2 spike protein 1 activates microvascular endothelial cells and complement system leading to platelet aggregation
Hazeldine et al. Neutrophils and COVID-19: active participants and rational therapeutic targets
US11819540B2 (en) Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
Katneni et al. Coagulopathy and thrombosis as a result of severe COVID-19 infection: a microvascular focus
Ning et al. The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication
Safronetz et al. Pathogenesis and host response in Syrian hamsters following intranasal infection with Andes virus
Aleksova et al. COVID‐19 and renin‐angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2)‐Is there any scientific evidence for controversy?
Johnson et al. Simian hemorrhagic fever virus infection of rhesus macaques as a model of viral hemorrhagic fever: clinical characterization and risk factors for severe disease
He et al. Mechanisms of SARS-CoV-2 infection-induced kidney injury: A literature review
Sayyadi et al. Status of major hemostatic components in the setting of COVID-19: the effect on endothelium, platelets, coagulation factors, fibrinolytic system, and complement
Li et al. FGL2–MCOLN3-Autophagy Axis–Triggered Neutrophil Extracellular Traps Exacerbate Liver Injury in Fulminant Viral Hepatitis
Arguinchona et al. Microvascular significance of TGF-β axis activation in COVID-19
Kumar et al. Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19
Drelich et al. Characterization of Unique Pathological Features of COVID-Associated Coagulopathy: Studies with AC70 hACE2 Transgenic Mice Highly Permissive to SARS-CoV-2 Infection
Sachetto et al. Tissue factor and COVID-19: an update
Blüm et al. Arterial thrombosis in the context of HCV-associated vascular disease can be prevented by protein C
US11723913B2 (en) Use of specific siRNA against protein S for the treatment of hemophilia
De Michele et al. SARS-CoV-2 infection predicts larger infarct volume in patients with acute ischemic stroke
Ball et al. Severe acute respiratory syndrome coronavirus 2 vasculopathy in a Syrian golden hamster model
Ebrahimi et al. Coagulation and Inflammation in COVID-19: Reciprocal Relationship between Inflammatory and Coagulation Markers
Perico et al. SARS-CoV-2 spike protein 1 activates microvascular endothelial cells and complement system leading to thrombus formation